Search results for " Local"

showing 10 items of 2101 documents

E-Cadherin gene expression in oral cancer: Clinical and prospective data

2019

Background Low protein expression of E-cadherin in oral squamous cell carcinoma (OSCC) has been associated with clinical and histopathological traits such as metastases, recurrence, low survival and poor tumor differentiation, and it is considered a high-risk marker of malignancy. However, it is still unknown whether low expression of E-cadherin is also present at the mRNA level in OSCC cases. Objective: The aim of this study was to compare E-cadherin mRNA expression in OSCC patients and controls and to correlate the expression with clinical and prospective characteristics. Material and Methods Forty patients and 40 controls were enrolled. E-cadherin mRNA expression was evaluated by quantit…

Oncologymedicine.medical_specialtyLow proteinMalignancyMetastasis03 medical and health sciences0302 clinical medicineInternal medicineGene expressionBiomarkers TumormedicineCarcinomaHumansProspective StudiesProspective cohort studyGeneral DentistryMouth neoplasmOral Medicine and PathologyE-Cadherinbusiness.industryResearchOral cancerCancer030206 dentistryCadherinsPrognosis:CIENCIAS MÉDICAS [UNESCO]medicine.diseasestomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellMouth NeoplasmsSurgeryGene expressionNeoplasm Recurrence LocalbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis

2018

Extranodal extension (ENE) of nodal metastasis is defined as the extension of metastatic cells through the nodal capsule into the perinodal tissue. This morphological parameter, recently proposed as an important prognostic factor in different types of malignancy, has not been included in the TNM staging system for non-small cell lung cancer (NSCLC). In this systematic review with meta-analysis, we weighted the prognostic role of ENE in patients with lymph node-positive NSCLC. Two independent authors searched SCOPUS and PubMed through 28 February 2017. Prospective and retrospective studies on NSCLC, comparing patients with presence of ENE (ENE+) ENE+) vs. only intranodal extension (ENE–) and…

Oncologymedicine.medical_specialtyLung NeoplasmsExtracapsular; Extranodal; Lung cancer; Metastasis; NSCLC; PrognosisTNM staging systemNSCLCMalignancyMetastasisPathology and Forensic MedicineMetastasis03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicine030212 general & internal medicineLung cancerMolecular BiologyEne reactionLung cancer . NSCLC . Prognosis . Extranodal . Extracapsular . MetastasisExtracapsularbusiness.industryHazard ratioRetrospective cohort studyCell BiologyGeneral MedicinePrognosismedicine.diseaseLymphatic Metastasis030220 oncology & carcinogenesisRelative riskExtranodalLymph NodesLung cancerNeoplasm Recurrence Localbusiness
researchProduct

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Int…

2011

The Gynecological Cancer Intergroup (GCIG) has previously reached consensus regarding the criteria that should be used in clinical trial protocols to define progression-free survival after first-line therapy as well as the criteria to define response to treatment in recurrent disease using the serum marker CA 125 and has specified the situations where these criteria should be used. However, the publications did not include detailed definitions, nor were they written to accommodate the new version of Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1) now available. Thus, we recommend that the definitions described later in detail are incorporated into clinical trial…

Oncologymedicine.medical_specialtyMEDLINEAntineoplastic AgentsDisease-Free SurvivalInternal medicinemedicineRecurrent diseaseHumansIn patientOvarian NeoplasmsClinical Trials as Topicbusiness.industryObstetrics and Gynecologymedicine.diseaseGynecological cancerResponse to treatmentSurgeryClinical trialOncologyResponse Evaluation Criteria in Solid TumorsCA-125 AntigenDisease ProgressionFemaleHuman medicineNeoplasm Recurrence LocalOvarian cancerbusiness
researchProduct

What is the prognostic importance of lymphovascular space invasion in the absence of lymph node metastasis for early-stage endometrial cancer?

2021

Objective: The aim of this study is to analyze the prognostic role of lymph-vascular space invasion (LVSI), evaluated in a semi-quantitative fashion on prognosis of early stage, low risk endometrial cancer (EC). Methods: We enrolled patients who underwent surgery for endometrial cancer between 2003 and 2018 in two referral cancer center. All patients had endometrioid EC, G1–G2, with myometrial invasion <50%, and no lymph-node involvement. LVSI was analyzed in a semi-quantitative way, according to a 3-tiered scoring system in absent, focal and substantial. Results: Among 524 patients, any positive LVSI was found in 57 patients (10.9%) with focal LVSI (n=35, 6.7%) and substantial LVSI (n=2…

Oncologymedicine.medical_specialtyMultivariate analysisLymph node metastasisEndometrial Cancer03 medical and health sciences0302 clinical medicineText miningInternal medicineMedicineHumansRisk factorStage (cooking)Neoplasm MetastasisLetter to the EditorUnivariate analysis030219 obstetrics & reproductive medicineEndometrial Cancer; Neoplasm Metastasis; Prognostic FactorsEndometrial Cancer Neoplasm Metastasis Prognostic Factorsbusiness.industryPrognostic FactorsEndometrial cancerHazard ratioCancerObstetrics and GynecologyGeneral Medicinemedicine.diseasePrognosisLymphovascularEndometrial NeoplasmsSettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionFemaleLymphNeoplasm Recurrence LocalbusinessCarcinoma EndometrioidJournal of gynecologic oncology
researchProduct

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE…

2021

International audience; Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper was to report 3-year oncological outcomes, representing the secondary endpoints of the PRODIGE 22 trial. Method PRODIGE 22 was a randomized multicentre phase II trial in high-risk T3, T4 and/or N2 CC patients on CT scan. Patients were randomized between 6 months of adjuvant FOLFOX (upfront surgery) or perioperative FOLFOX (four cycles before surgery and eight cycles after; FOLFOX perioperative). In wild-type RAS patients, a third arm testing perioperative FOLFOX-cetuximab was added. The pri…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancer[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinsurvival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationNeoplasm StagingColectomyeducation.field_of_studybusiness.industryHazard ratioGastroenterologyPerioperativecolectomyPrognosisInterim analysismedicine.diseaseNeoadjuvant Therapydigestive system diseasescolon cancerChemotherapy Adjuvant030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFluorouracilNeoplasm Recurrence Localbusinessneoadjuvant chemotherapyFollow-Up Studiesmedicine.drugColorectal Disease
researchProduct

Role of robotic surgery in ovarian malignancy

2017

As part of minimally invasive surgery, robotic-assisted approach is becoming increasingly popular in gynecologic oncology. It has been shown to be effective and feasible for staging and treating endometrial and cervical cancer, but its role in the context of primary and recurrent ovarian cancers is presently debated. Scanty data are available in the literature, and the level of evidence supporting its use in ovarian cancer is quite low. However, from a retrospective case-control series, robotic surgery seems to be safe and feasible for early-stage ovarian cancer. Its use in treating patients with advanced-stage or relapsed ovarian cancer is still highly controversial, suggesting the choice …

Oncologymedicine.medical_specialtyPopulationContext (language use)robotic surgery ovarian cancerGynecologic oncologygynecologic oncology03 medical and health sciencesGynecologic Surgical Procedures0302 clinical medicineRobotic Surgical ProceduresInternal medicinerobotic surgerymedicineHumansRobotic surgeryeducationOvarian malignancygynecologic oncology; minimally invasive surgery; ovarian cancer; robotic surgery; Obstetrics and Gynecologyminimally invasive surgeryNeoplasm StagingRetrospective StudiesOvarian NeoplasmsCervical cancereducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryGeneral surgeryObstetrics and GynecologyGeneral MedicineEvidence-based medicinemedicine.diseasegynecologic oncology; minimally invasive surgery; ovarian cancer; robotic surgery; Case-Control Studies; Female; Gynecologic Surgical Procedures; Humans; Neoplasm Recurrence Local; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Robotic Surgical Procedures; Treatment OutcomeTreatment Outcomeovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIACase-Control Studies030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessOvarian cancer
researchProduct

Tumor Size, an Additional Risk Factor of Local Recurrence in Low-Risk Endometrial Cancer: A Large Multicentric Retrospective Study.

2018

ObjectiveThe identification of patients with endometrial cancer (EC) at higher risk for relapse is critical to individualize and better tailor postoperative treatment. No evidence is available regarding the possible association between tumor size (TS) and the risk of local recurrence. The purpose of this study was to analyze the correlation between TS and risk/type of recurrence in EC patients, stratified according to the new European Society of Medical Oncology-European Society of Gynecological Oncology-European Society for Radiotherapy and Oncology classification.MethodsData of patients with histologically proven EC who received primary surgical treatment between November 1999 and June 20…

Oncologymedicine.medical_specialtyPrognostic factormedicine.medical_treatmentRome03 medical and health sciencesEndometrium0302 clinical medicineEndometrial cancerRetrospective StudieRisk FactorsInternal medicinemedicineLocal recurrenceHumansEndometrial NeoplasmRisk factorAgedRetrospective Studies030219 obstetrics & reproductive medicineReceiver operating characteristicTumor sizebusiness.industryRisk FactorEndometrial cancerDistant relapseLocal relapseObstetrics and GynecologyRetrospective cohort studyTumor sizeMiddle Agedmedicine.diseaseEndometrial NeoplasmsRadiation therapyEndometrial cancer; Local recurrence; Local relapse; Tumor size; Vaginal relapse; Oncology; Obstetrics and GynecologyNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIALocalReproductive MedicineOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessVaginal relapseHumanInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Progress of Phototherapy Applications in the Treatment of Bone Cancer

2021

Bone cancer including primary bone cancer and metastatic bone cancer, remains a challenge claiming millions of lives and affecting the life quality of survivors. Conventional treatments of bone cancer include wide surgical resection, radiotherapy, and chemotherapy. However, some bone cancer cells may remain or recur in the local area after resection, some are highly resistant to chemotherapy, and some are insensitive to radiotherapy. Phototherapy (PT) including photodynamic therapy (PDT) and photothermal therapy (PTT), is a clinically approved, minimally invasive, and highly selective treatment, and has been widely reported for cancer therapy. Under the irradiation of light of a specific wa…

Oncologymedicine.medical_specialtyQH301-705.5Photothermal Therapymedicine.medical_treatmentCancer therapyBone NeoplasmsPhotodynamic therapyReviewCatalysisInorganic ChemistryInternal medicineHumansMedicineBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopyOsteosarcomaChemotherapyPhotosensitizing Agentsbusiness.industryBone cancerOrganic ChemistryCancerbone cancerGeneral MedicinePhototherapyPhotothermal therapymedicine.diseaseComputer Science ApplicationsRadiation therapyChemistryPrimary bonephotodynamic therapyPhotochemotherapyNanoparticlesGoldtumor therapyNeoplasm Recurrence LocalReactive Oxygen SpeciesbusinessInternational Journal of Molecular Sciences
researchProduct

Cetuximab in squamous cell head and neck carcinomas.

2007

The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been shown to enhance the effects of radiotherapy, and reports to date indicate that this effect occurs without any change in the pattern and severity of toxicity usually associated with head and neck radiation and/or chemotherapy (CT) administration. Moreover, several studies have reported that the expression of EGFR is strongly linked to poor outcome in patients undergoing therapy. Therefore, the presence of the EGFR in almost all cases of head and neck carcinoma offers a new therapeutic opportunity to most patients. In this paper, we report a review of the major studies dealing with the use of cetuximab in ad…

Oncologymedicine.medical_specialtyRadiation-Sensitizing Agentsmedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineCarcinomaAnimalsHumansEpidermal growth factor receptorSquamous epithelial cellCetuximabbiologyClinical Trials Phase I as Topicbusiness.industryHead and neck cancerAntibodies MonoclonalHematologymedicine.diseaseHead and neck squamous-cell carcinomaChemotherapy regimenRadiation therapyneck carcinomasmedicine.anatomical_structureOncologyHead and Neck Neoplasmsbiology.proteinCarcinoma Squamous CellNeoplasm Recurrence Localbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Tumor biology in older breast cancer patients – What is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohor…

2015

Abstract Purpose The tumor biology of older breast cancer patients (oBCP) is usually less aggressive, however applied adjuvant treatment is often less potent resulting in an impaired disease free survival and overall survival in this group. This study tries to answer the following questions for the biological subtypes of oBCP (70+ y): (1) Is there a significant difference in the distribution of the biological subtypes of oBCP vs younger breast cancer patients (yBCP; 50–69 y)? (2) Which biological subtype has the highest rate of non-guideline-adherent-treatment (GL−) among oBCP? (3) Is a single GL− (i.e. radiotherapy/surgery/endocrine-therapy/chemotherapy) significantly associated with the s…

Oncologymedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentBreast NeoplasmsBreast cancerGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedRetrospective StudiesChemotherapybusiness.industryTumor biologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseSurvival AnalysisRadiation therapyTreatment OutcomeChemotherapy AdjuvantHormone receptorFemaleSurgeryGuideline AdherenceHealth Impact AssessmentNeoplasm Recurrence LocalbusinessAdjuvantCohort studyThe Breast
researchProduct